LA JOLLA, Calif., June 26 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Duska Therapeutics is published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under the Blue Sky Laws. Standard Corporation Records is available in print, on CD-ROM, and via the Web at http://www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.
The Duska Therapeutics corporate information now available through the Records Listing Program includes an in-depth description of the Company's business operations, share price, dividend history, shares outstanding, company's financial position, earnings, and full income statement and balance sheet.
Earlier this month Duska Therapeutics announced it has been granted an exclusive worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. The lead candidate is expected to enter Phase II clinical trials later this year.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology
company focused on the development of medical products based on adenosine
triphosphate and nitric oxide. Duska owns or has exclusive licensing rights
to proprietary medical products that are in various stages of development
for the treatment and diagnosis of certain cardiac arrhythmias, treatment
of heart failure, treatment of chronic obstructive pulmonary disorder, and
|SOURCE Duska Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved